The addition of Onivyde (MM-398) to 5-fluorouracil (5-FU) and leucovorin significantly improved overall survival (OS) while having no negative impact on quality of life (QOL) for patients with metastatic pancreatic cancer, according to an analysis of the phase 3 NAPOLI-1 trial presented at the 2016 World Congress on Gastrointestinal (GI) Cancer, a gathering of oncology professionals from around the world in Barcelona, Spain.
“This quality of life analysis of the NAPOLI-1 data underscores the significant clinical benefit the Onivyde regimen provides to a patient population with few treatment options,” Richard Hubner, an investigator on the NAPOLI-1 trial and Consultant Medical Oncologist at Christie NHS Foundation Trust, said in a statement. Read more . . .